US6927A
(en)
|
|
1849-12-04 |
|
Improvement in pumps for raising water |
US69A
(en)
|
|
1836-10-27 |
|
Machine eor picking or breaking wool and ginned or seedless cotton |
US366A
(en)
|
|
1837-08-31 |
|
Quadrant hinge foe |
US138A
(en)
|
|
1837-03-08 |
|
Barnabas s |
US5866A
(en)
|
|
1848-10-17 |
|
Dentist s deill |
US6649A
(en)
|
|
1849-08-14 |
|
Arrangement of steam-boiler |
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4888278A
(en)
|
1985-10-22 |
1989-12-19 |
University Of Massachusetts Medical Center |
In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
|
US5447841A
(en)
|
1986-01-16 |
1995-09-05 |
The Regents Of The Univ. Of California |
Methods for chromosome-specific staining
|
US6280929B1
(en)
|
1986-01-16 |
2001-08-28 |
The Regents Of The University Of California |
Method of detecting genetic translocations identified with chromosomal abnormalities
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4774339A
(en)
|
1987-08-10 |
1988-09-27 |
Molecular Probes, Inc. |
Chemically reactive dipyrrometheneboron difluoride dyes
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
AU634186B2
(en)
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5132432A
(en)
|
1989-09-22 |
1992-07-21 |
Molecular Probes, Inc. |
Chemically reactive pyrenyloxy sulfonic acid dyes
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5274113A
(en)
|
1991-11-01 |
1993-12-28 |
Molecular Probes, Inc. |
Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
|
US5433896A
(en)
|
1994-05-20 |
1995-07-18 |
Molecular Probes, Inc. |
Dibenzopyrrometheneboron difluoride dyes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5248782A
(en)
|
1990-12-18 |
1993-09-28 |
Molecular Probes, Inc. |
Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
|
US5338854A
(en)
|
1991-02-13 |
1994-08-16 |
Molecular Probes, Inc. |
Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
|
US5427932A
(en)
|
1991-04-09 |
1995-06-27 |
Reagents Of The University Of California |
Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
|
US5187288A
(en)
|
1991-05-22 |
1993-02-16 |
Molecular Probes, Inc. |
Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US5505928A
(en)
|
1991-11-22 |
1996-04-09 |
The Regents Of University Of California |
Preparation of III-V semiconductor nanocrystals
|
US5262357A
(en)
|
1991-11-22 |
1993-11-16 |
The Regents Of The University Of California |
Low temperature thin films formed from nanocrystal precursors
|
ATE297465T1
(de)
|
1991-11-25 |
2005-06-15 |
Enzon Inc |
Verfahren zur herstellung von multivalenten antigenbindenden proteinen
|
DK1087013T3
(da)
|
1992-08-21 |
2009-05-11 |
Univ Bruxelles |
Immunoglobuliner uden lette kæder
|
US6048616A
(en)
|
1993-04-21 |
2000-04-11 |
Philips Electronics N.A. Corp. |
Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
|
US5472842A
(en)
|
1993-10-06 |
1995-12-05 |
The Regents Of The University Of California |
Detection of amplified or deleted chromosomal regions
|
EP0690452A3
(fr)
|
1994-06-28 |
1999-01-07 |
Advanced Micro Devices, Inc. |
Mémoire électriquement effaçable et procédé d'effacement
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
US5571018A
(en)
|
1994-11-23 |
1996-11-05 |
Motorola, Inc. |
Arrangement for simulating indirect fire in combat training
|
EP0739981A1
(fr)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5690807A
(en)
|
1995-08-03 |
1997-11-25 |
Massachusetts Institute Of Technology |
Method for producing semiconductor particles
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
US5800996A
(en)
|
1996-05-03 |
1998-09-01 |
The Perkin Elmer Corporation |
Energy transfer dyes with enchanced fluorescence
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
US5830912A
(en)
|
1996-11-15 |
1998-11-03 |
Molecular Probes, Inc. |
Derivatives of 6,8-difluoro-7-hydroxycoumarin
|
US5696157A
(en)
|
1996-11-15 |
1997-12-09 |
Molecular Probes, Inc. |
Sulfonated derivatives of 7-aminocoumarin
|
US5866366A
(en)
|
1997-07-01 |
1999-02-02 |
Smithkline Beecham Corporation |
gidB
|
US6130101A
(en)
|
1997-09-23 |
2000-10-10 |
Molecular Probes, Inc. |
Sulfonated xanthene derivatives
|
US6322901B1
(en)
|
1997-11-13 |
2001-11-27 |
Massachusetts Institute Of Technology |
Highly luminescent color-selective nano-crystalline materials
|
US6207392B1
(en)
|
1997-11-25 |
2001-03-27 |
The Regents Of The University Of California |
Semiconductor nanocrystal probes for biological applications and process for making and using such probes
|
US5990479A
(en)
|
1997-11-25 |
1999-11-23 |
Regents Of The University Of California |
Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6566131B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad6 expression
|
US6410323B1
(en)
|
1999-08-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of human Rho family gene expression
|
US6617583B1
(en)
|
1998-09-18 |
2003-09-09 |
Massachusetts Institute Of Technology |
Inventory control
|
US6114038A
(en)
|
1998-11-10 |
2000-09-05 |
Biocrystal Ltd. |
Functionalized nanocrystals and their use in detection systems
|
US6855202B2
(en)
|
2001-11-30 |
2005-02-15 |
The Regents Of The University Of California |
Shaped nanocrystal particles and methods for making the same
|
US6107091A
(en)
|
1998-12-03 |
2000-08-22 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of G-alpha-16 expression
|
US5981732A
(en)
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
US6046321A
(en)
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
AU4701200A
(en)
|
1999-05-07 |
2000-11-21 |
Quantum Dot Corporation |
A method of detecting an analyte using semiconductor nanocrystals
|
ES2269171T3
(es)
|
1999-07-26 |
2007-04-01 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal |
Dispositivo en capas con regiones de captura para analisis celular.
|
US7214477B1
(en)
|
1999-07-26 |
2007-05-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Layered device with capture regions for cellular analysis
|
US7838222B2
(en)
|
1999-07-26 |
2010-11-23 |
United States of America/ NIH |
Methods, devices and kits for multiplex blotting of biological samples from multi-well plates
|
US6969615B2
(en)
|
1999-07-26 |
2005-11-29 |
20/20 Genesystems, Inc. |
Methods, devices, arrays and kits for detecting and analyzing biomolecules
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
EP1212422B1
(fr)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Anticorps contre l'antigene ctla-4 humain et utilisation
|
US6225198B1
(en)
|
2000-02-04 |
2001-05-01 |
The Regents Of The University Of California |
Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
|
US6306736B1
(en)
|
2000-02-04 |
2001-10-23 |
The Regents Of The University Of California |
Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
|
JP2004500109A
(ja)
|
2000-03-22 |
2004-01-08 |
クァンタム・ドット・コーポレイション |
ビーズベースの核酸アッセイにおける半導体ナノクリスタルの使用方法
|
JP2003535063A
(ja)
|
2000-06-01 |
2003-11-25 |
ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティー |
放射線医薬としてのナノ粒子のバイオコンジュゲート
|
US6365354B1
(en)
|
2000-07-31 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of lysophospholipase I expression
|
DE60136719D1
(de)
|
2000-08-04 |
2009-01-08 |
Molecular Probes Inc |
Kondensierte ringe enthaltende 1,2-dihydro-7-hydroxychinolinderivate
|
US6942970B2
(en)
|
2000-09-14 |
2005-09-13 |
Zymed Laboratories, Inc. |
Identifying subjects suitable for topoisomerase II inhibitor treatment
|
US6566135B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of caspase 6 expression
|
US6649138B2
(en)
|
2000-10-13 |
2003-11-18 |
Quantum Dot Corporation |
Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
|
US20020083888A1
(en)
|
2000-12-28 |
2002-07-04 |
Zehnder Donald A. |
Flow synthesis of quantum dot nanocrystals
|
US6670113B2
(en)
|
2001-03-30 |
2003-12-30 |
Nanoprobes |
Enzymatic deposition and alteration of metals
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
US6709929B2
(en)
|
2001-06-25 |
2004-03-23 |
North Carolina State University |
Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
|
US20060073141A1
(en)
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
ATE556845T1
(de)
|
2001-07-20 |
2012-05-15 |
Life Technologies Corp |
Lumineszierende nanopartikel und ihre herstellung
|
WO2003042402A2
(fr)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
|
ATE395413T1
(de)
|
2001-12-03 |
2008-05-15 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
GB0229734D0
(en)
|
2002-12-23 |
2003-01-29 |
Qinetiq Ltd |
Grading oestrogen and progesterone receptors expression
|
US7257268B2
(en)
|
2003-02-28 |
2007-08-14 |
Aperio Technologies, Inc. |
Systems and methods for image pattern recognition
|
ES2428941T3
(es)
|
2003-03-10 |
2013-11-12 |
Expression Pathology, Inc. |
Preparación líquida de tejidos a partir de muestras biológicas, tejidos y células procesadas histopatológicamente
|
US7642064B2
(en)
|
2003-06-24 |
2010-01-05 |
Ventana Medical Systems, Inc. |
Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
|
ES2330441T3
(es)
|
2003-06-24 |
2009-12-10 |
Ventana Medical Systems, Inc. |
Deposito de metal catalizado por una enzima para la deteccion in situ mejorada de epitopos inmunohistoquimicos y secuencias de acido nucleico.
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
EP1893241A2
(fr)
|
2005-04-28 |
2008-03-05 |
Ventana Medical Systems, Inc. |
Nanoparticules flourescentes conjuguées á des anticorps via un linker peg
|
ES2609919T3
(es)
|
2005-04-28 |
2017-04-25 |
Ventana Medical Systems, Inc. |
Enzimas conjugados con anticuerpos mediante un conector de PEG heterobifuncional
|
CA2970873C
(fr)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
CN101535244B
(zh)
|
2005-11-23 |
2014-07-23 |
文塔納医疗系统公司 |
分子缀合物
|
JP5537034B2
(ja)
|
2005-12-23 |
2014-07-02 |
ナノストリング テクノロジーズ,インコーポレーテッド |
ナノレポーターならびにその作製方法および使用方法
|
US8986926B2
(en)
|
2005-12-23 |
2015-03-24 |
Nanostring Technologies, Inc. |
Compositions comprising oriented, immobilized macromolecules and methods for their preparation
|
US7629125B2
(en)
|
2006-11-16 |
2009-12-08 |
General Electric Company |
Sequential analysis of biological samples
|
US7741045B2
(en)
|
2006-11-16 |
2010-06-22 |
General Electric Company |
Sequential analysis of biological samples
|
WO2008119353A1
(fr)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Anticorps bispécifiques et procédés de production de ceux-ci
|
JP5555157B2
(ja)
|
2007-04-10 |
2014-07-23 |
ナノストリング テクノロジーズ, インコーポレイテッド |
ナノレポーターにおける使用のための標的特異的配列を同定するための方法およびコンピュータシステム
|
US8023714B2
(en)
|
2007-06-06 |
2011-09-20 |
Aperio Technologies, Inc. |
System and method for assessing image interpretability in anatomic pathology
|
EP3222634A1
(fr)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Anticorps dirigés contre le récepteur humain de mort programmée pd-1
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
EP2331704B1
(fr)
|
2008-08-14 |
2016-11-30 |
Nanostring Technologies, Inc |
Nanoreporteurs stables
|
ES2573945T3
(es)
|
2008-09-16 |
2016-06-13 |
Novartis Ag |
Cuantificación reproducible de expresión de biomarcadores
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2010083252A2
(fr)
|
2009-01-14 |
2010-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarqueurs basés sur des taux et méthodes d'utilisation associées
|
WO2010089411A2
(fr)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
US20110111435A1
(en)
|
2009-11-06 |
2011-05-12 |
SlidePath Limited |
Detecting Cell Surface Markers
|
WO2011066342A2
(fr)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Inhibition simultanée de pd-l1/pd-l2
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
SG184427A1
(en)
|
2010-04-20 |
2012-11-29 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
KR101846590B1
(ko)
|
2010-06-11 |
2018-04-09 |
교와 핫꼬 기린 가부시키가이샤 |
항 tim-3 항체
|
WO2011159877A2
(fr)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
WO2012168944A1
(fr)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Composés thérapeutiques pour une immunomodulation
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2822957A1
(fr)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Composés peptidomimétiques utilisés comme immunomodulateurs
|
CA2868408A1
(fr)
|
2012-03-29 |
2013-10-03 |
Aurigene Discovery Technologies Limited |
Composes cycliques d'immunomodulation provenant de la boucle bc de pd1 humain
|
LT3401400T
(lt)
|
2012-05-25 |
2019-06-10 |
The Regents Of The University Of California |
Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
|
EP2903692B1
(fr)
*
|
2012-10-08 |
2019-12-25 |
St. Jude Children's Research Hospital |
Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine
|
EP4234696A3
(fr)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Systèmes de composants crispr-cas, procédés et compositions pour la manipulation de séquence
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
DK2898075T3
(en)
|
2012-12-12 |
2016-06-27 |
Broad Inst Inc |
CONSTRUCTION AND OPTIMIZATION OF IMPROVED SYSTEMS, PROCEDURES AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
PT2970155T
(pt)
|
2013-03-15 |
2018-07-02 |
Bristol Myers Squibb Co |
Inibidores de indoleamina 2,3-dioxigenase (ido)
|
HUP1300432A2
(hu)
|
2013-07-10 |
2015-01-28 |
Tamas Kardos |
Downhill kerékpár szerkezet javított felfüggesztéssel
|
RS57559B1
(sr)
|
2013-09-06 |
2018-10-31 |
Aurigene Discovery Tech Ltd |
1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori
|
SG11201601682RA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,2,4-oxadiazole derivatives as immunomodulators
|
WO2015036927A1
(fr)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Dérivés peptidomimétiques d'immunomodulation
|
US20160237455A1
(en)
|
2013-09-27 |
2016-08-18 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
ES2847311T3
(es)
|
2014-08-05 |
2021-08-02 |
MabQuest SA |
Reactivos inmunológicos que se unen a PD-1
|
WO2017055404A1
(fr)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anticorps bispécifiques spécifiques de pd1 et tim3
|
WO2017075451A1
(fr)
*
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1
|
WO2018087143A2
(fr)
*
|
2016-11-08 |
2018-05-17 |
Actigen Ltd |
Anticorps anti-pd-1
|
JOP20190134A1
(ar)
*
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
RU2019141270A
(ru)
*
|
2017-05-16 |
2021-06-16 |
Иммуноджен, Инк. |
Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
|
EP3630842A2
(fr)
*
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunothérapeutique
|
AU2018280340A1
(en)
*
|
2017-06-05 |
2019-12-19 |
The Council Of The Queensland Institute Of Medical Research |
A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor.
|
WO2020109627A1
(fr)
*
|
2018-11-30 |
2020-06-04 |
Institut Gustave Roussy |
Polythérapie anti-neuropiline-1 et anti-mort cellulaire programmée 1 pour le traitement du cancer
|